These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30714680)

  • 1. Impact of chronic kidney disease on long-term clinical outcomes of everolimus-eluting stent implantation: A subanalysis of the Tokyo-MD PCI registry.
    Miyazaki T; Ashikaga T; Asano M; Sasaoka T; Kurihara K; Yoshikawa S; Isobe M;
    Catheter Cardiovasc Interv; 2019 Jul; 94(1):E9-E16. PubMed ID: 30714680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus Eluting Stents in Patients with Diabetes Mellitus and Chronic Kidney Disease: Insights from the TUXEDO Trial.
    Bangalore S; Abhaichand R; Mullasari A; Jain R; Chand RKP; Arambam P; Kaul U
    Cardiovasc Revasc Med; 2019 Dec; 20(12):1075-1080. PubMed ID: 31036397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term clinical outcomes of permanent-polymer everolimus-eluting stent implantation following rotational atherectomy for severely calcified de novo coronary lesions: Results of a 22-center study (Tokyo-MD PCI Study).
    Otaki Y; Ashikaga T; Sasaoka T; Kurihara K; Yoshikawa S; Isobe M;
    Cardiovasc Revasc Med; 2019 Feb; 20(2):120-125. PubMed ID: 29861332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and predictors of early and late target lesion revascularization after everolimus-eluting stent implantation in unselected patients in japan.
    Kurihara K; Ashikaga T; Sasaoka T; Yoshikawa S; Isobe M;
    Catheter Cardiovasc Interv; 2017 Jul; 90(1):78-86. PubMed ID: 28295926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical outcomes after coronary artery bypass graft versus everolimus-eluting stent implantation in chronic hemodialysis patients.
    Kumada Y; Ishii H; Aoyama T; Kamoi D; Sakakibara T; Umemoto N; Ito R; Takahashi H; Murohara T
    Coron Artery Dis; 2018 Sep; 29(6):489-494. PubMed ID: 29668554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice.
    Zanchin C; Ueki Y; Zanchin T; Häner J; Otsuka T; Stortecky S; Koskinas KC; Siontis GCM; Praz F; Moschovitis A; Hunziker L; Valgimigli M; Pilgrim T; Heg D; Windecker S; Räber L
    JACC Cardiovasc Interv; 2019 Sep; 12(17):1665-1675. PubMed ID: 31422088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of total stent length after cobalt chromium everolimus-eluting stent implantation on 3-year clinical outcomes.
    Hiromasa T; Kuramitsu S; Shinozaki T; Jinnouchi H; Morinaga T; Kobayashi Y; Domei T; Soga Y; Shirai S; Ando K
    Catheter Cardiovasc Interv; 2017 Feb; 89(2):207-216. PubMed ID: 26910036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus-eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Post-Approval studies.
    Guedeney P; Claessen BE; Mehran R; Kandzari DE; Aquino M; Davis S; Tamis L; Wang JC; Othman I; Gigliotti OS; Haghighat A; Singh S; Lopez M; Giugliano G; Horwitz PA; Sorrentino S; Underwood P; Allocco D; Meredith IT; Batchelor W
    Catheter Cardiovasc Interv; 2019 Jul; 94(1):82-90. PubMed ID: 30666784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
    Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes in real-world patients with bifurcation lesions receiving Xience V everolimus-eluting stents: Four-year results from the Xience V USA study.
    Hermiller JB; Applegate RJ; Baird C; Butler MM; Rutledge D; Wang J; Kakarala K; Krucoff MW; Sudhir K
    Catheter Cardiovasc Interv; 2016 Jul; 88(1):62-70. PubMed ID: 26399687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-eluting stents in patients on chronic hemodialysis: paclitaxel-eluting stents vs. limus-eluting stents.
    Sardi GL; Loh JP; Torguson R; Laynez-Carnicero A; Kitabata H; Xue Z; Satler LF; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2014 Mar; 15(2):86-91. PubMed ID: 24684759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).
    Maeng M; Baranauskas A; Christiansen EH; Kaltoft A; Holm NR; Krusell LR; Ravkilde J; Tilsted HH; Thayssen P; Jensen LO
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1161-7. PubMed ID: 25640050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial.
    Crimi G; Leonardi S; Costa F; Adamo M; Ariotti S; Valgimigli M
    Int J Cardiol; 2016 Jun; 212():110-7. PubMed ID: 27038714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization.
    Yamaji K; Zanchin T; Zanchin C; Stortecky S; Koskinas KC; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Valgimigli M; Billinger M; Pilgrim T; Heg D; Windecker S; Räber L
    Circ Cardiovasc Interv; 2018 Sep; 11(9):e006741. PubMed ID: 30354590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents.
    Alfonso F; Pérez-Vizcayno MJ; Cuesta J; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Cequier A; Velázquez M; Moreno R; Mainar V; Domínguez A; Moris C; Molina E; Rivero F; Jiménez-Quevedo P; Gonzalo N; Fernández-Pérez C;
    JACC Cardiovasc Interv; 2018 May; 11(10):981-991. PubMed ID: 29798776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-year outcomes after revascularization with everolimus- and sirolimus-eluting stents from the SORT OUT IV trial.
    Jensen LO; Thayssen P; Maeng M; Christiansen EH; Ravkilde J; Hansen KN; Kaltoft A; Tilsted HH; Madsen M; Lassen JF;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):840-8. PubMed ID: 25086842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.
    Mahmoud AN; Barakat AF; Elgendy AY; Schneibel E; Mentias A; Abuzaid A; Elgendy IY
    Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28468954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of real-world patients treated with an amphilimus polymer-free stent versus new generation everolimus-eluting stents.
    Panoulas VF; Latib A; Naim C; Sato K; Ielasi A; Tespili M; Godino C; Testa L; Bedogni F; Colombo A
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1168-76. PubMed ID: 26269415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.